GlassScriptPhysician profile
John F Mcatee
NPI 1255413910
$4,801.22
in general payments reported to CMS, 2019-2025
35 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $738 · 2021: $954 · 2022: $1,167 · 2023: $667 · 2024: $151 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.42 | 2021-2023 | |
| Amgen INC. | $569.57 | 2019-2025 | Evenity, Prolia, Otezla |
| Amarin Pharma, INC. | $466.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $427.12 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.71 | 2019-2023 | Xifaxan |
| Esperion Therapeutics, INC. | $278.67 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $228.45 | 2019-2025 | Airsupra |
| Eisai INC. | $223.23 | 2020-2022 | |
| Astellas Pharma US INC | $216.87 | 2019-2025 | Veozah |
| Novo Nordisk INC | $175.40 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Ironshore Pharmaceuticals INC. | $142.58 | 2019 | |
| Pfizer INC. | $119.75 | 2020-2025 | |
| Lilly USA, LLC | $88.38 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $87.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $81.38 | 2020-2023 | Belsomra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $58.68 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $51.23 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.46 | 2022 | |
| Daiichi Sankyo INC. | $45.17 | 2023 | Injectafer |
| Sunovion Pharmaceuticals INC. | $43.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $38.37 | 2019 | |
| Abbott Laboratories | $33.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.22 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.32 | 2022-2023 | Quviviq |
| Cleerly, INC. | $29.56 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Aytu Biopharma, INC. | $28.50 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.44 | 2019 | |
| Allergan, INC. | $27.32 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.90 | 2023 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $25.31 | 2021 | |
| Sumitomo Pharma America, INC. | $19.99 | 2024 | Gemtesa |
| Neotract INC. | $19.96 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.08 | 2022 | |
| Bausch Health US, LLC | $14.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcatee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.